Table 1.

The characteristics of 92 patients with pediatric BCP-ALL and 11 with pediatric T-ALL with PRMT5 expression in bone marrow cells

Number of casesPRMT5 Ratio (mean ± SD)Statistical valueP
BCP-ALL
 Sex
  Male541.15 ± 0.340.9020.369
  Female381.08 ± 0.38
 Age (years)
  <10700.93 ± 0.273.0450.003
  ≥10221.18 ± 0.36
 Immunophenotype
  Pro-B70.79 ± 0.220.2950.034
  Common-B801.17 ± 0.34
  Pre-B50.78 ± 0.23
 Oncogene fusion
  BCR/ABL60.873 ± 0.260.9310.450
  TEL/AML1211.11 ± 0.31
  E2A/PBX151.21 ± 0.47
  Other601.13 ± 0.35
 PRa
  PGR721.12 ± 0.35−0.2190.827
  PPR71.15 ± 0.19
 Bone marrow response after induction therapya
  CR751.12 ± 0.240.2620.610
  No CR41.04 ± 0.11
 Risk groupa
  SR291.17 ± 0.341.9930.612
  IR401.07± 0.36
  HR101.03 ± 0.25
T-ALL
 Sex
  Male81.31 ± 0.53-0.6810.513
  Female31.55 ± 0.52
 Age (years)
  <1041.68 ± 0.651.6950.131
  ≥1071.19 ± 0.36
 PR
  PGR61.42 ± 0.590.8170.827
  PPR51.23 ± 0.41
 Risk group
  IR61.49 ± 0.590.7740.459
  HR51.23 ± 0.41
  • aOne patient died during the induction therapy, 12 patients returned to the local hospital for treatment after diagnosis in the 92 patients, so 79 patients could be followed and assessed the complete remission, risk group, and PR.

  • Abbreviations: PGR, prednisone good response; PPR, prednisone poor response; T-ALL, T-cell ALL.